Blood Diagnostics Partnerships And NETs Platform Will Drive Long Term Upside Potential

Catalysts

About VolitionRx

VolitionRx develops blood based diagnostic tests built on its Nu.Q nucleosome platform for applications across human and veterinary health.

What are the underlying business or industry changes driving this perspective?

• Growing focus on blood based cancer and sepsis diagnostics, combined with VolitionRx's Nu.Q platform and recently submitted Capture Seq paper, can widen test adoption and support higher product and licensing revenue over time.
• Industry interest in NETosis across autoimmune disease, sepsis and thrombosis, together with the Nu.Q NETs H3.1 assay already CE marked in the EU and evaluated in 14 hospital networks, can create a broader clinical use case that lifts recurring test volumes and revenue.
• Partnerships with large diagnostics companies such as Werfen and Hologic, each with global installed bases and established customer relationships, can shorten VolitionRx's commercial ramp and support higher licensing income and milestone receipts.
• Expansion of Nu.Q Vet into centralized automated lab platforms such as the IDS i10 with partners including Fujifilm Vet Systems, Antech and IDEXX, and the push toward inclusion in annual pet wellness panels, can increase test throughput and improve gross margins and earnings power.
• Ongoing cost discipline, including lower operating expenses and reduced cash used in operations, paired with potential new human diagnostics licensing deals across NETs and oncology, can improve operating leverage and narrow net losses as revenue scales.

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming VolitionRx's revenue will grow by 130.6% annually over the next 3 years.
• Analysts are not forecasting that VolitionRx will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate VolitionRx's profit margin will increase from -997.5% to the average US Medical Equipment industry of 11.8% in 3 years.
• If VolitionRx's profit margin were to converge on the industry average, you could expect earnings to reach $3.6 million (and earnings per share of $0.35) by about July 2029, up from -$24.6 million today.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 63.7x on those 2029 earnings, up from -0.5x today. This future PE is greater than the current PE for the US Medical Equipment industry at 26.6x.
• Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 9.41%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• The human diagnostics business is still very early, with quarterly revenue of US$0.6 million and management describing revenues as lumpy and hard to predict. If partnerships with Werfen, Hologic and other potential licensees do not convert into broad commercial launches, long term revenue could fall short of expectations and delay any path toward positive earnings.
• VolitionRx is investing heavily in complex technologies such as Nu.Q NETs and Capture Seq that rely on clinical validation and peer reviewed publications. If larger diagnostics and liquid biopsy players develop alternative approaches to NETs or background DNA removal, VolitionRx could lose differentiation, which would pressure pricing power and future net margins.
• The company’s goal of becoming cash neutral depends on securing several significant human diagnostics licensing agreements and milestone payments in the veterinary segment. Any delay in closing these deals, publishing the feline cancer paper or achieving usage milestones for Nu.Q Vet wellness panels could extend the period of cash burn and keep net losses elevated.
• Regulatory and clinical adoption timelines are uncertain, as Nu.Q NETs is still under evaluation in 14 hospital networks and early lung cancer work in France and Taiwan has yet to move into broad routine use. Slower than hoped uptake or inconclusive clinical utility data could limit test volumes and constrain both revenue growth and earnings.
• VolitionRx operates in large markets such as cancer and sepsis with an addressable market of about US$25b and an APS opportunity of about US$85 million annually. However, with many well funded competitors and rapidly evolving science, the company may need sustained spending on research, commercialization and partnerships just to defend its position, which could cap long term net margin improvement even if topline revenue increases.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of $16.97 for VolitionRx based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $24.0, and the most bearish reporting a price target of just $4.0.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $30.2 million, earnings will come to $3.6 million, and it would be trading on a PE ratio of 63.7x, assuming you use a discount rate of 9.4%.
• Given the current share price of $1.34, the analyst price target of $16.97 is 92.1% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.